Clinical pharmacology of antifungal compounds.
Prompted by the worldwide surge in fungal infections, the past decade has witnessed a considerable expansion in antifungal drug research. New compounds have entered the clinical arena, and major progress has been made in defining paradigms of antifungal therapies. This article provides an up-to-date review on the clinical pharmacology, indications, and dosage recommendations of approved and currently investigational therapeutics for treatment of invasive fungal infections in adult and pediatric patients.
Infectious Disease Research Program, Center for Bone Marrow Transplantation, Department of Pediatric Hematology/Oncology, Wilhelms-University Medical Center, Domagkstrasse 9a, 48149 Muenster, Germany. grollan@mednet.uni-muenster.de
Andreas H
AH
Groll
Juan C
JC
Gea-Banacloche
Axel
A
Glasmacher
Gudrun
G
Just-Nuebling
Georg
G
Maschmeyer
Thomas J
TJ
Walsh
D000900:Anti-Bacterial Agents / Q000145:classification / Q000378:metabolism / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D015195:Drug Design; D054714:Echinocandins; D005437:Flucytosine / Q000378:metabolism / Q000494:pharmacology; D005656:Fungal Proteins; D006801:Humans; D016867:Immunocompromised Host; D015394:Molecular Structure; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control; D010455:Peptides; D010456:Peptides, Cyclic; D011090:Polyenes / Q000145:classification / Q000493:pharmacokinetics; D014230:Triazoles / Q000145:classification / Q000493:pharmacokinetics
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D005656:Fungal Proteins; D010455:Peptides; D010456:Peptides, Cyclic; D011090:Polyenes; D014230:Triazoles; C007572:echinocandin B; D005437:Flucytosine